You are here
Global Diagnostic Imaging Partnering 2014-2019: Access to Agreements by the Worlds Leading Healthcare Companies
DUBLIN, June 11, 2019 /PRNewswire/ -- The "Global Diagnostic Imaging Partnering Terms and Agreements 2014 to 2019" report has been added to ResearchAndMarkets.com's offering.
The Global Diagnostic Imaging Partnering Terms and Agreements 2014 to 2019 report provides comprehensive understanding and unprecedented access to the diagnostic imaging partnering agreements entered into by the worlds leading healthcare companies.
This report provides an overview of diagnostic imaging dealmaking, the common clauses, rights and options in the partnering agreement, and also a comprehensive review of deals signed in since 2014.
This report provides a comprehensive and detailed review of all diagnostic imaging deals announced since 2014. The comprehensive agreements chapter is organized by company A-Z, stage of development at signing, deal type, and therapy focus.
Contract documents provide unsurpassed access to the detail of a deal normally announced in brief summary through a press release. Detailed analysis of a contract allow better understanding of the terms agreed between the parties, and importantly the basis under which monies and licensing rights are exchanged.
The initial chapters of this report provide an orientation of Diagnostic Imaging dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Diagnostic Imaging dealmaking since 2014, including details of average headline, upfront, milestone and royalty terms.
Chapter 3 provides a review of the leading Diagnostic Imaging deals since 2014. Deals are listed by headline value, signed by big pharma, most active Diagnostic Imaging dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 4 provides a comprehensive listing of the top 25 most active companies in Diagnostic Imaging dealmaking with a brief summary followed by a comprehensive listing of Diagnostic Imaging deals, as well as contract documents available in the public domain.
Chapter 5 provides a comprehensive and detailed review of Diagnostic Imaging partnering deals signed and announced since Jan 2014, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus.
Chapter 7 provides a comprehensive and detailed review of Diagnostic Imaging partnering deals signed and announced since Jan 2014. The chapter is organized by specific Diagnostic Imaging technology type in focus.
In addition, a comprehensive appendix is provided organized by Diagnostic Imaging partnering company A-Z, deal type definitions and Diagnostic Imaging partnering agreements example.
The report also includes numerous tables and figures that illustrate the trends and activities in Diagnostic Imaging partnering and dealmaking since 2014.
This report provides details of the latest diagnostics agreements announced in the healthcare sectors, covering:
- Molecular and nuclear
- X ray
- In-depth understanding of diagnostic deal trends since 2014
- Analysis of the structure of diagnostic agreements with numerous real life case studies
- Comprehensive access to over 500 actual diagnostic imaging deals entered into by the world's biopharma companies
- Detailed access to actual diagnostic contracts enter into by the leading biopharma companies
- Insight into the terms included in a diagnostic agreement, together with real world clause examples
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Available contracts are listed by:
- Headline value
- Stage of development at signing
- Deal component type
- Specific therapy target
- Specific technology target
Key Topics Covered:
Chapter 1 - Introduction
Chapter 2 - Trends in Diagnostic Imaging dealmaking
2.2. Diagnostic Imaging partnering over the years
2.3. Most active Diagnostic Imaging dealmakers
2.4. Diagnostic Imaging partnering by deal type
2.5. Diagnostic Imaging partnering by therapy area
2.6. Deal terms for Diagnostic Imaging partnering
2.6.1 Diagnostic Imaging partnering headline values
2.6.2 Diagnostic Imaging deal upfront payments
2.6.3 Diagnostic Imaging deal milestone payments
2.6.4 Diagnostic Imaging royalty rates
Chapter 3 - Leading Diagnostic Imaging deals
3.2. Top Diagnostic Imaging deals by value
Chapter 4 - Most active Diagnostic Imaging dealmakers
4.2. Most active Diagnostic Imaging dealmakers
4.3. Most active Diagnostic Imaging partnering company profiles
Chapter 5 - Diagnostic Imaging contracts dealmaking directory
5.2. Diagnostic Imaging contracts dealmaking directory
Chapter 6 - Diagnostic Imaging dealmaking by technology type
Chapter 7 - Partnering resource center
7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking
Appendix 1 - Diagnostic Imaging deals by company A-Z
Appendix 2 - Diagnostic Imaging deals by stage of development
Appendix 3 - Diagnostic Imaging deals by deal type
Manufacturing - OEM
Appendix 4 - Diagnostic Imaging deals by therapy area
Central Nervous System
Appendix 5 - Deal type definitions
For more information about this report visit https://www.researchandmarkets.com/r/dgwrt
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets